Funding
Funding not disclosed
Founders
Product
Problem
Developing novel genetic medicines faces significant hurdles in efficiently delivering therapeutic payloads to target cells and ensuring precise control over gene expression. This limits the therapeutic window and efficacy of current gene therapy approaches for a range of genetic disorders.
Solution
Collage.Bio is engineering a proprietary platform for next-generation genetic medicine, focusing on advanced delivery systems and precise gene regulation. Our approach utilizes novel molecular constructs designed for enhanced cellular uptake and targeted tissue distribution. We are developing a system that allows for tunable gene expression, enabling therapeutic proteins to be produced at optimal levels within the patient. This technology aims to overcome the limitations of current gene therapies, offering improved safety and efficacy profiles for a broader spectrum of genetic conditions.
Target Audience
Our primary target audience includes biotechnology companies and pharmaceutical partners seeking to advance their gene therapy pipelines with innovative delivery and expression technologies.
Features
- Novel lipid nanoparticle (LNP) formulation for enhanced intracellular delivery of genetic material.
- Engineered mRNA constructs with optimized codon usage and 5' UTR sequences for increased translational efficiency.
- Self-amplifying RNA (saRNA) technology for sustained protein expression from a single administration.
- Targeted delivery mechanisms utilizing specific ligand-receptor interactions for tissue-specific gene expression.
- In vivo screening platform for rapid optimization of delivery vectors and therapeutic payloads.